JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McElmurray, J. H.
Right arrow Articles by Spinale, F. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McElmurray, J. H., III
Right arrow Articles by Spinale, F. G.

Vol. 291, Issue 2, 799-811, November 1999

Angiotensin-Converting Enzyme and Matrix Metalloproteinase Inhibition with Developing Heart Failure: Comparative Effects on Left Ventricular Function and Geometry1

James H. McElmurray, III2, Rupak Mukherjee2, R. Brent New2, Angela C. Sampson2, Mary K. King2, Jennifer W. Hendrick2, Aron Goldberg2, Thomas J. Peterson4, Hussein Hallak4, Michael R. Zile3 and Francis G. Spinale2

Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina

The progression of congestive heart failure (CHF) is left ventricular (LV) myocardial remodeling. The matrix metalloproteinases (MMPs) contribute to tissue remodeling and therefore MMP inhibition may serve as a useful therapeutic target in CHF. Angiotensin converting enzyme (ACE) inhibition favorably affects LV myocardial remodeling in CHF. This study examined the effects of specific MMP inhibition, ACE inhibition, and combined treatment on LV systolic and diastolic function in a model of CHF. Pigs were randomly assigned to five groups: 1) rapid atrial pacing (240 beats/min) for 3 weeks (n = 8); 2) ACE inhibition (fosinopril, 2.5 mg/kg b.i.d. orally) and rapid pacing (n = 8); 3) MMP inhibition (PD166793 2 mg/kg/day p.o.) and rapid pacing (n = 8); 4) combined ACE and MMP inhibition (2.5 mg/kg b.i.d. and 2 mg/kg/day, respectively) and rapid pacing (n = 8); and 5) controls (n = 9). LV peak wall stress increased by 2-fold with rapid pacing and was reduced in all treatment groups. LV fractional shortening fell by nearly 2-fold with rapid pacing and increased in all treatment groups. The circumferential fiber shortening-systolic stress relation was reduced with rapid pacing and increased in the ACE inhibition and combination groups. LV myocardial stiffness constant was unchanged in the rapid pacing group, increased nearly 2-fold in the MMP inhibition group, and was normalized in the ACE inhibition and combination treatment groups. Increased MMP activation contributes to the LV dilation and increased wall stress with pacing CHF and a contributory downstream mechanism of ACE inhibition is an effect on MMP activity.


0022-3565/99/2912-0799$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Exp PhysiolHome page
P. Castro-Chaves, R. Fontes-Carvalho, M. Pintalhao, P. Pimentel-Nunes, and A. F. Leite-Moreira
Angiotensin II-induced increase in myocardial distensibility and its modulation by the endocardial endothelium in the rabbit heart
Exp Physiol, June 1, 2009; 94(6): 665 - 674.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
F. G. Spinale
Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function
Physiol Rev, October 1, 2007; 87(4): 1285 - 1342.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. L. Brower, S. P. Levick, and J. S. Janicki
Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3057 - H3064.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Paolocci, B. Tavazzi, R. Biondi, Y. A. Gluzband, A. M. Amorini, C. G. Tocchetti, M. Hejazi, P. M. Caturegli, J. Kajstura, G. Lazzarino, et al.
Metalloproteinase Inhibitor Counters High-Energy Phosphate Depletion and AMP Deaminase Activity Enhancing Ventricular Diastolic Compliance in Subacute Heart Failure
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 506 - 513.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. M. Deschamps, K. A. Apple, A. H. Leonardi, J. E. McLean, W. M. Yarbrough, R. E. Stroud, L. L. Clark, J. A. Sample, and F. G. Spinale
Myocardial Interstitial Matrix Metalloproteinase Activity Is Altered by Mechanical Changes in LV Load: Interaction With the Angiotensin Type 1 Receptor
Circ. Res., May 27, 2005; 96(10): 1110 - 1118.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. Heymans, F. Lupu, S. Terclavers, B. Vanwetswinkel, J.-M. Herbert, A. Baker, D. Collen, P. Carmeliet, and L. Moons
Loss or Inhibition of uPA or MMP-9 Attenuates LV Remodeling and Dysfunction after Acute Pressure Overload in Mice
Am. J. Pathol., January 1, 2005; 166(1): 15 - 25.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Sundstrom, J. C. Evans, E. J. Benjamin, D. Levy, M. G. Larson, D. B. Sawyer, D. A. Siwik, W. S. Colucci, P. Sutherland, P. W.F. Wilson, et al.
Relations of Plasma Matrix Metalloproteinase-9 to Clinical Cardiovascular Risk Factors and Echocardiographic Left Ventricular Measures: The Framingham Heart Study
Circulation, June 15, 2004; 109(23): 2850 - 2856.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Y. Sakata, K. Yamamoto, T. Mano, N. Nishikawa, J. Yoshida, M. Hori, T. Miwa, and T. Masuyama
Activation of Matrix Metalloproteinases Precedes Left Ventricular Remodeling in Hypertensive Heart Failure Rats: Its Inhibition as a Primary Effect of Angiotensin-Converting Enzyme Inhibitor
Circulation, May 4, 2004; 109(17): 2143 - 2149.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Diwan, Z. Dibbs, S. Nemoto, G. DeFreitas, B. A. Carabello, N. Sivasubramanian, E. M. Wilson, F. G. Spinale, and D. L. Mann
Targeted Overexpression of Noncleavable and Secreted Forms of Tumor Necrosis Factor Provokes Disparate Cardiac Phenotypes
Circulation, January 20, 2004; 109(2): 262 - 268.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
W. M. Yarbrough, R. Mukherjee, G. P. Escobar, J. A. Sample, J. E. McLean, K. B. Dowdy, J. W. Hendrick, W. C. Gibson, A. E. Hardin, J. T. Mingoia, et al.
Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathway
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1892 - 1899.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. M. Yarbrough, R. Mukherjee, G. P. Escobar, J. T. Mingoia, J. A. Sample, J. W. Hendrick, K. B. Dowdy, J. E. McLean, A. S. Lowry, T. P. O'Neill, et al.
Selective Targeting and Timing of Matrix Metalloproteinase Inhibition in Post-Myocardial Infarction Remodeling
Circulation, October 7, 2003; 108(14): 1753 - 1759.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Qun Gao, G. Sawicki, W. L Suarez-Pinzon, T. Csont, M. Wozniak, P. Ferdinandy, and R. Schulz
Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction
Cardiovasc Res, February 1, 2003; 57(2): 426 - 433.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. F. Baicu, J. D. Stroud, V. A. Livesay, E. Hapke, J. Holder, F. G. Spinale, and M. R. Zile
Changes in extracellular collagen matrix alter myocardial systolic performance
Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H122 - H132.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
D Reinhardt, H H Sigusch, J Hensse, S C Tyagi, R Korfer, and H R Figulla
Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP
Heart, December 1, 2002; 88(5): 525 - 530.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Y. Li, T. Kadokami, P. Wang, C. F. McTiernan, and A. M. Feldman
MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure
Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H983 - H989.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. T. Peterson, H. Hallak, L. Johnson, H. Li, P. M. O'Brien, D. R. Sliskovic, T. M. A. Bocan, M. L. Coker, T. Etoh, and F. G. Spinale
Matrix Metalloproteinase Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in a Rat Model of Progressive Heart Failure
Circulation, May 8, 2001; 103(18): 2303 - 2309.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
F. G Spinale, M. L Coker, B. R Bond, and J. L Zellner
Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target
Cardiovasc Res, May 1, 2000; 46(2): 225 - 238.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. Li, H. Simon, T. M.A. Bocan, and J.T. Peterson
MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition
Cardiovasc Res, May 1, 2000; 46(2): 298 - 306.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J.T. Peterson, H. Li, L. Dillon, and J. W. Bryant
Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat
Cardiovasc Res, May 1, 2000; 46(2): 307 - 315.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. L. Chancey, G. L. Brower, J. T. Peterson, and J. S. Janicki
Effects of Matrix Metalloproteinase Inhibition on Ventricular Remodeling Due to Volume Overload
Circulation, April 23, 2002; 105(16): 1983 - 1988.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.